Entry Point Capital, LLC Intra Cellular Therapies, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 1,268 shares of ITCI stock, worth $114,766. This represents 0.13% of its overall portfolio holdings.
Number of Shares
1,268
Previous 2,167
41.49%
Holding current value
$114,766
Previous $150 Million
42.09%
% of portfolio
0.13%
Previous 0.13%
Shares
3 transactions
Others Institutions Holding ITCI
# of Institutions
401Shares Held
87.5MCall Options Held
301KPut Options Held
277K-
Vanguard Group Inc Valley Forge, PA9.61MShares$870 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$572 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.72MShares$337 Million1.37% of portfolio
-
Jpmorgan Chase & CO New York, NY3.44MShares$311 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$272 Million2.8% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8.54B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...